GRI Bio, Inc. GRI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
13/100
Weak

About GRI Bio, Inc.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such … Full GRI analysis →

Competitive advantage assessment

Key risks

  • ROIC Below WACC or Peers ROIC at 15.3th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.10), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where GRI ranks in Biotechnology

GRI Bio, Inc. ranks #632 of 713 scored companies in Biotechnology by moat score — the top 89%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near GRI in Biotechnology
# Company Moat score Rating
628 Genelux Corporation GNLX 14/100 Weak
629 Estrella Immunopharma, Inc. ESLAW 13/100 Weak
630 Clearmind Medicine Inc. CMND 13/100 Weak
631 InflaRx N.V. IFRX 13/100 Weak
632 GRI Bio, Inc. GRI 13/100 Weak
633 Reviva Pharmaceuticals Holdings RVPHW 13/100 Weak
634 Actuate Therapeutics, Inc. ACTU 13/100 Weak
635 Reviva Pharmaceuticals Holdings RVPH 12/100 Weak
636 Vincerx Pharma, Inc. VINC 12/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How GRI scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 8 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 20 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding GRI's moat

What is GRI Bio, Inc.'s moat score?

GRI Bio, Inc. (GRI) scores 13 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #632 of 713 scored companies in Biotechnology, the top 89%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (20/100) and its weakest is Capital Efficiency (8/100).

How does GRI Bio, Inc. compare with other Biotechnology companies?

GRI Bio, Inc. ranks #632 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are InflaRx N.V. (IFRX) at 13 just above it and Reviva Pharmaceuticals Holdings (RVPHW) at 13 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is GRI Bio, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for GRI Bio, Inc.?

The Corporate Default template measures 6 defenses, and GRI scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (8), Resilience (20), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000